These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 30262849)
1. Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2- Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study. Zhao Y; Liu C; Zhang Y; Gong C; Li Y; Xie Y; Wu B; Yang Z; Wang B Sci Rep; 2018 Sep; 8(1):14458. PubMed ID: 30262849 [TBL] [Abstract][Full Text] [Related]
2. Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031 [TBL] [Abstract][Full Text] [Related]
3. Whole-Body Metabolic Tumor Volume, as Determined by (18)F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis. Son SH; Lee SW; Jeong SY; Song BI; Chae YS; Ahn BC; Lee J AJR Am J Roentgenol; 2015 Oct; 205(4):878-85. PubMed ID: 26204115 [TBL] [Abstract][Full Text] [Related]
4. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer. Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424 [TBL] [Abstract][Full Text] [Related]
5. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study. Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701 [TBL] [Abstract][Full Text] [Related]
6. Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer. Li Y; Liu C; Wang B; Hu X; Gong C; Zhao Y; Xie Y; Zhang Y; Song S; Yang Z; Wang B Int J Gen Med; 2021; 14():1797-1809. PubMed ID: 34007206 [TBL] [Abstract][Full Text] [Related]
7. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369 [TBL] [Abstract][Full Text] [Related]
8. The Predictive Value of Early Changes in He M; Liu C; Shi Q; Sun Y; Zhang Y; Xu X; Yuan H; Zhang Y; Liu Y; Liu G; Di G; Yang Z; Wang Z; Shao Z Oncologist; 2020 Nov; 25(11):927-936. PubMed ID: 32272493 [TBL] [Abstract][Full Text] [Related]
9. Risk stratification in patients with advanced-stage breast cancer by pretreatment [(18) F]FDG PET/CT. Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC Cancer; 2015 Nov; 121(22):3965-74. PubMed ID: 26249241 [TBL] [Abstract][Full Text] [Related]
10. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228 [TBL] [Abstract][Full Text] [Related]
11. Prognostic predictive value of preoperative intratumoral 2-deoxy-2-(18F)fluoro-D-glucose uptake heterogeneity in patients with high-grade serous ovarian cancer. Liu S; Feng Z; Jiang Z; Wen H; Xu J; Pan H; Deng Y; Zhang L; Ju X; Chen X; Wu X Nucl Med Commun; 2018 Oct; 39(10):928-935. PubMed ID: 29771717 [TBL] [Abstract][Full Text] [Related]
12. [Correlations of Wang JL; Shi AQ; Fan CC; Wang YZ; Guo GR; Liu JY Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Aug; 44(4):628-635. PubMed ID: 36065696 [TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents. Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043 [TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer. Lee JW; Kang CM; Choi HJ; Lee WJ; Song SY; Lee JH; Lee JD J Nucl Med; 2014 Jun; 55(6):898-904. PubMed ID: 24711649 [TBL] [Abstract][Full Text] [Related]
15. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma. Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082 [TBL] [Abstract][Full Text] [Related]
16. Combined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer. Miccò M; Vargas HA; Burger IA; Kollmeier MA; Goldman DA; Park KJ; Abu-Rustum NR; Hricak H; Sala E Eur J Radiol; 2014 Jul; 83(7):1169-1176. PubMed ID: 24767630 [TBL] [Abstract][Full Text] [Related]
17. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma]. Ding CY; Guo Z; Sun J; Yang WP; Li TR Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362 [No Abstract] [Full Text] [Related]
18. Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment? Evangelista L; Cervino AR; Ghiotto C; Saibene T; Michieletto S; Fernando B; Orvieto E; Guarneri V; Conte P Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1648-1655. PubMed ID: 26025244 [TBL] [Abstract][Full Text] [Related]
19. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas. Ryu IS; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902 [TBL] [Abstract][Full Text] [Related]
20. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma. Lim R; Eaton A; Lee NY; Setton J; Ohri N; Rao S; Wong R; Fury M; Schöder H J Nucl Med; 2012 Oct; 53(10):1506-13. PubMed ID: 22895812 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]